[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650256":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":30,"centralContacts":39,"locations":45,"responsibleParty":58,"collaborators":30,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":30,"eligibilityCriteria":67,"healthyVolunteers":64,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":30,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":48,"whyStopped":30,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1 (control group):","ACTIVE_COMPARATOR","will include 22 patients who will receive the conventional therapy for RA for 3 months.",[13],"Drug: Convential medical treatment",{"label":15,"type":10,"description":16,"interventionNames":17},"Group 2 (diosmin group):","will include 22 patients who will receive the conventional therapy for RA plus 1000 mg diosmin once daily for 3 months.",[18,13],"Drug: Diosmin",{"label":20,"type":10,"description":21,"interventionNames":22},"Group 3 (rebamipide group):","will include 22 patients who will receive the conventional therapy for RA plus 100 mg rebamipide three times daily for 3 months.",[23,13],"Drug: Rebamipide 100mg",[25,31,35],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Diosmin","1000 mg diosmin once daily for 3 months",[15],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"Rebamipide 100mg","100 mg rebamipide three times daily for 3 months",[20],{"type":26,"name":36,"description":37,"armGroupLabels":38,"otherNames":30},"Convential medical treatment","conventional medical treatment for RA",[9,15,20],[40],{"name":41,"role":42,"phone":43,"phoneExt":30,"email":44},"khlood mohamed kettana, assistant lecturer","CONTACT","01091100037","khlood.kettana@pharm.tanta.edu.eg",[46],{"facility":47,"status":48,"city":49,"state":30,"zip":30,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":30},"Faculty of Pharmacy Tanta University","RECRUITING","Tanta","Egypt","EG",{"type":53,"coordinates":54},"Point",[55,56],31.00192,30.78847,{"lat":56,"lon":55},{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"PRINCIPAL_INVESTIGATOR","Khlood Mohamed Kettana","clinical pharmacy assistant lecturer","100650256","phase-2-clinical-study-comparing-diosmin-vs-rebamipide-as-adjuvant-therapies-vs-conventional-therapy-in-patients-with-rheumatoid-arthritis-100650256",false,"NCT07745426","Clinical Study Comparing Diosmin vs Rebamipide as Adjuvant Therapies vs Conventional Therapy in Patients With Rheumatoid Arthritis","Inclusion Criteria:\n\n* Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology\u002FEuropean League Against Rheumatism (ACR\u002FEULAR). i.e.,28 joints disease activity score (DAS-28) \\>2.6.\n* Both sexes.\n* Age ranges between 18 and 70 years old.\n* Patients receiving conventional DMARDs\n\nExclusion Criteria:\n\n* Pregnant and lactating females.\n* Patients receiving biological DMARDs or targeted synthetic DMARDs.\n* Patients with renal and hepatic dysfunction.\n* Patients with other inflammatory\u002Fautoimmune diseases, active infection, or malignancies.\n* Patients with bleeding disorders, receiving warfarin or other anticoagulants.\n* Patients receiving antioxidants.\n* Patients with hypersensitivity to study medications.","ALL","18 Years","70 Years",{"count":72,"type":73},66,"ESTIMATED","INTERVENTIONAL",[76],"PHASE2","This study will be a randomized controlled parallel study that will be conducted on 66 patients with active rheumatoid arthritis who will be diagnosed with RA according to American College of Rheumatology (ACR)\u002FEuropean League Against Rheumatism (EULAR, 2010). The patients will be recruited from Outpatient Clinic of Rheumatology, Physical Medicine, Rheumatology and Rehabilitation Department, Tanta University Hospital, Tanta, Egypt. The study duration will be 3 months. The patients will be randomized into three groups:\n\n\\- Group 1 (control group): will include 22 patients who will receive the conventional therapy for RA for 3 months.\n\n\\- Group 2 (diosmin group): will include 22 patients who will receive the conventional therapy for RA plus 1000 mg diosmin once daily for 3 months.\n\n\\- Group 3 (rebamipide group): will include 22 patients who will receive the conventional therapy for RA plus 100 mg rebamipide three times daily for 3 months.",[79],"Rheumatoid Arthritis (RA)",[81,82,83],"rheumatoid arthritis","diosmin","rebamipide","2026-07-29",{"date":86,"type":87},"2026-08-04","ACTUAL",{"date":89,"type":73},"2026-08-01",{"date":91,"type":73},"2027-08-01",{"name":5,"class":6},1]